Research Article
Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR167653
Masataka Nishikawa,
Akira Myoui,
Tetsuya Tomita,
Koichiro Takahi,
Akihide Nampei,
Hideki Yoshikawa,
Masataka Nishikawa
Osaka University Graduate School of Medicine, Osaka, Japan
Search for more papers by this authorCorresponding Author
Akira Myoui
Osaka University Graduate School of Medicine, Osaka, Japan
Department of Orthopaedics, Osaka University Graduate School of Medicine 2-2 Yamada-oka, Suita, Osaka 565-0871, JapanSearch for more papers by this authorTetsuya Tomita
Osaka University Graduate School of Medicine, Osaka, Japan
Search for more papers by this authorKoichiro Takahi
Osaka University Graduate School of Medicine, Osaka, Japan
Search for more papers by this authorAkihide Nampei
Osaka University Graduate School of Medicine, Osaka, Japan
Search for more papers by this authorHideki Yoshikawa
Osaka University Graduate School of Medicine, Osaka, Japan
Search for more papers by this authorMasataka Nishikawa,
Akira Myoui,
Tetsuya Tomita,
Koichiro Takahi,
Akihide Nampei,
Hideki Yoshikawa,
Masataka Nishikawa
Osaka University Graduate School of Medicine, Osaka, Japan
Search for more papers by this authorCorresponding Author
Akira Myoui
Osaka University Graduate School of Medicine, Osaka, Japan
Department of Orthopaedics, Osaka University Graduate School of Medicine 2-2 Yamada-oka, Suita, Osaka 565-0871, JapanSearch for more papers by this authorTetsuya Tomita
Osaka University Graduate School of Medicine, Osaka, Japan
Search for more papers by this authorKoichiro Takahi
Osaka University Graduate School of Medicine, Osaka, Japan
Search for more papers by this authorAkihide Nampei
Osaka University Graduate School of Medicine, Osaka, Japan
Search for more papers by this authorHideki Yoshikawa
Osaka University Graduate School of Medicine, Osaka, Japan
Search for more papers by this authorAbstract
Objective
FR167653 is a potent inhibitor of p38 mitogen-activated protein kinase (MAPK) and inhibits tumor necrosis factor α (TNFα) and interleukin-1β (IL-1β) production in inflammatory cells. In this study we investigated the effect of FR167653 on collagen-induced arthritis (CIA).
Methods
Rats with CIA were subcutaneously injected with FR167653 (32 mg/kg/day) starting on the day of the booster injection (day 7) in the prophylactic treatment group and after the onset of arthritis (day 21) in the therapeutic treatment group. Hind-paw swelling, body weight, radiographic and histologic scores, and osteoclast number were evaluated. Cytokine levels in the serum and tissue were assessed by enzyme-linked immunosorbent assays. Flow cytometric analysis of T lymphocytes from bone marrow was performed. The effect of FR167653 on in vitro osteoclast formation induced by soluble receptor activator of nuclear factor κB ligand (sRANKL) and TNFα was examined.
Results
Swelling of hind paws and loss of weight occurred in the CIA rats, but this was not evident in the prophylactic treatment group. Therapeutic treatment also significantly reduced paw swelling. The mean radiographic and histologic scores as well as the osteoclast numbers were significantly lower in the treatment group than in the CIA rats without treatment. FR167653 treatment reduced the serum levels of TNFα and IL-1β, lowered the IL-1β concentration in the ankle joints, and decreased the CD4−,CD8a+ T cell population in bone marrow. Furthermore, FR167653 inhibited the osteoclast-like cell differentiation induced by both sRANKL and TNFα in vitro.
Conclusion
FR167653 prevents the onset of arthritis in a prophylactic treatment model and suppresses the progression of joint destruction in a therapeutic treatment model, suggesting that p38 MAPK is a potential therapeutic target for rheumatoid arthritis.
REFERENCES
- 1 Suzuki M, Tetsuka T, Yoshida S, Watanabe N, Kobayashi M, Matsui M, et al. The role of p38 mitogen-activated protein kinase in IL-6 and IL-8 production from the TNF-α- or IL-1β-stimulated rheumatoid synovial fibroblast. FEBS Lett 2000; 465: 23–7.
- 2 Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996; 14: 397–440.
- 3 Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 1996; 85: 307–10.
- 4 Durie FH, Fava RA, Noelle R. Short analytical review: collagen-induced arthritis as a model of rheumatoid arthritis. Clin Immunol Immunopathol 1994; 73: 11–8.
- 5 Sasai M, Saeki Y, Ohshima S, Nishioka K, Mima T, Tanaka T, et al. Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6–deficient mice. Arthritis Rheum 1999; 42: 1635–43.
- 6 Goldring SR, Gravallese EM. Pathogenesis of bone lesions in rheumatoid arthritis. Curr Rheumatol Rep 2000; 4: 226–31.
- 7 Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999; 18: 304–9.
- 8 Romas E, Gillespie MT, Martin TJ. Involvement of receptor activator of NFκB ligand and tumor necrosis factor-α in bone destruction in rheumatoid arthritis. Bone 2002; 30: 340–6.
- 9 Arend WP, Dayer J-M. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum 1995; 38: 151–60.
- 10 Feldmann M, Elliot MJ, Woody JN, Maini RN. Anti-tumor necrosis factor-α therapy of rheumatoid arthritis. Adv Immunol 1997; 64: 283–350.
- 11 Breedveld FC. Future trends in the treatment of rheumatoid arthritis: cytokine targets. Rheumatology 1998; 38 Suppl 2: 11–3.
- 12 Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989; 2: 244–7.
- 13 Wooley PH, Duthcer J, Widmer MB, Gillis S. Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol 1993; 151: 6602–7.
- 14 Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleishmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337: 141–7.
- 15 Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999; 130: 478–86.
- 16 Jarvis B, Faulds D. Etanercept: a review of its use in rheumatoid arthritis. Drugs 1999; 57: 945–66.
- 17 Moreland LW, Cohen SB, Baumgartner SW, Tindall EA, Bulpitt K, Martin R, et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001; 28: 1238–44.
- 18 Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti–tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552–63.
- 19 Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999; 354: 1932–9.
- 20 Kavanaugh A, St Clair EW, McCune WJ, Braakman T, Lipsky P. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol 2000; 27: 841–50.
- 21 Antoni C, Kalden JR. Combination therapy of the chimeric monoclonal anti-tumor necrosis factor alpha antibody (Infliximab) with methotrexate in patients with rheumatoid arthritis. Clin Exp Rheumatol 1999; 17 Suppl 18: S73–7.
- 22 Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105–10.
- 23 Arend WP. Interleukin-1 receptor antagonist: discovery, structure and properties. Prog Growth Factor Res 1990; 2: 193–205.
- 24 Bendele AM, Chlipala ES, Scherrer J, Frazier J, Sennello G, Rich WJ, et al. Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. Arthritis Rheum 2000; 43: 2648–59.
- 25 Gabay C, Marinova-Mutafchieva L, Williams RO, Gigley JP, Butler DM, Feldmann M, et al. Increased production of intracellular interleukin-1 receptor antagonist type I in the synovium of mice with collagen-induced arthritis: a possible role in the resolution of arthritis. Arthritis Rheum 2001; 44: 451–62.
- 26 Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four–week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 614–24.
- 27 Bemelmans MHA, Gouma DJ, Buurman WA. Influence of nephrectomy on TNF receptor clearance in murine model. J Immunol 1993; 150: 2007–17.
- 28 Lipsky PE, Kavanaugh A. The impact of pharmaco-economic considerations on the utilization of novel anti-rheumatic therapies. Rheumatology 1999; 38 Suppl 2: 41–4.
- 29 Kalden JR. How do the biologics fit into the current DMARD armamentarium? J Rheumatol 2001; 28 Suppl 62: 27–35.
- 30 Yamamoto N, Sakai F, Yamazaki H, Nakahara K, Okuhara M. Effect of FR167653, a cytokine suppressive agent, on endotoxin-induced disseminated intravascular coagulation. Eur J Pharmacol 1996; 314: 137–42.
- 31 Yamamoto N, Sakai F, Yamazaki H, Nakahara K, Okuhara M. FR167653, a dual inhibitor of interleukin-1 and tumor necrosis factor-alpha, ameliorates endotoxin-induced shock. Eur J Pharmacol 1997; 327: 169–75.
- 32 Takahashi S, Keto Y, Fujita T, Uchiyama T, Yamamoto A. FR167653, a p38 mitogen-activated protein kinase inhibitor, prevents Helicobacter pylori-induced gastritis in Mongolian gerbils. J Pharmacol Exp Ther 2001; 296: 48–56.
- 33 Kawashima Y, Takeyoshi I, Otani Y, Koibuchi Y, Yoshinari D, Koyama T, et al. FR167653 attenuates ischemia and reperfusion injury of the rat lung with suppressing p38 mitogen-activated protein kinase. J Heart Lung Transplant 2001; 20: 568–74.
- 34 Yoshinari D, Takeyoshi I, Koibuchi Y, Matsumoto K, Kawashima Y, Koyama T, et al. Effects of a dual inhibitor of tumor necrosis factor-α and interleukin-1 on lipopolysaccharide-induced lung injury in rats: involvement of the p38 mitogen-activated protein kinase pathway. Crit Care Med 2001; 29: 628–34.
- 35 Miyazawa K, Mori A, Miyata H, Akahane M, Ajisawa Y, Okudaira H. Regulation of interleukin-1-β-induced interleukin-6 gene expression in human fibroblast-like synoviocytes by p38 mitogen-activated protein kinase. J Biol Chem 1998; 273: 24832–8.
- 36 Van den Berg WB, Joosten LA, Helsen MM, van de Loo FA. Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment. Clin Exp Immunol 1994; 95: 237–43.
- 37 Joosten LAB, Helsen MMA, van de Loo FAJ, van den Berg WB. Anticytokine treatment of established type II collagen–induced arthritis in DBA/1 mice: a comparative study using anti-TNFα, anti–IL-1α/β, and IL-1Ra. Arthritis Rheum 1996; 39: 797–809.
- 38 Mussener A, Litton MJ, Lindroos E, Klareskog L. Cytokine production in synovial tissue of mice with collagen-induced arthritis (CIA). Clin Exp Immunol 1997; 107: 485–93.
- 39 Marinova-Mutafchieva L, Williams RO, Mason LJ, Mauri C, Feldmann M, Maini RN. Dynamics of proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis (CIA). Clin Exp Immunol 1997; 107: 507–12.
- 40 Trentham D, Townes A, Kang A. Autoimmunity to type II collagen: an experimental model of arthritis. J Exp Med 1977; 146: 857–68.
- 41 Tomita T, Takeuchi E, Tomita N, Morishita R, Kaneko M, Yamamoto K, et al. Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor κB decoy oligodeoxynucleotides as a gene therapy. Arthritis Rheum 1999; 42: 2532–42.
- 42 Cuzzocrea S, Mazzon E, Dugo L, Serraino I, Britti D, De Maio M, et al. Absence of endogenous interleukin-10 enhances the evolution of murine type-II collagen-induced arthritis. Eur Cytokine Netw 2001; 12: 568–80.
- 43 Shiozawa S, Shimizu K, Tanaka K, Hino K. Studies on the contribution of c-fos/AP-1 to arthritic joint destruction. J Clin Invest 1997; 99: 1210–6.
- 44 Takeshita S, Kaji K, Kudo A. Identification and characterization of the new osteoclast progenitor with macrophage phenotypes being able to differentiate into mature osteoclasts. J Bone Miner Res 2000; 15: 1477–88.
- 45 Badger AM, Griswold DE, Kapadia R, Blake S, Swift BA, Hoffman SJ, et al. Disease-modifying activity of SB242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. Arthritis Rheum 2000; 43: 175–83.
- 46 Shinozaki T, Takagishi K, Tsutsumi S, Yanagawa T, Takeuchi K, Watanabe H, et al. Effect of FR167653, a dual inhibitor of interleukin-1 and tumor necrosis factor, on adjuvant arthritis in rats. Mod Rheumatol 2001; 11: 300–3.
- 47 Aiba M, Takeyoshi I, Sunose Y, Iwazaki S, Tsutsumi H, Ohwada S, et al. FR167653 ameliorates pulmonary damage in ischemia-reperfusion injury in a canine lung transplantation model. J Heart Lung Transplant 2000; 19: 879–86.
- 48 Kobayashi N, Kataoka T, Ono A, Tsukimi Y, Okabe S. Role of p38 mitogen-activated protein kinase in the healing of gastric ulcers in rats. J Physiol Pharmacol 2001; 52: 195–210.
- 49 Kitada H, Sugitani A, Yamamoto H, Otomo N, Okabe Y, Inoue S, et al. Attenuation of renal ischemia-reperfusion injury by FR167653 in dogs. Surgery 2002; 131: 654–62.
- 50 Kong YM, Waldmann H, Cobbold S, Giraldo AA, Fuller BE, Simon LL. Pathogenic mechanisms in murine autoimmune thyroiditis: short- and long-term effects of in vivo depletion of CD4+ and CD8+ cells. Clin Exp Immunol 1989; 77: 428–33.
- 51 Mozes E, Kohn LD, Hakim F, Singer DS. Resistance of MHC class I-deficient mice to experimental systemic lupus erythematosus. Science 1993; 261: 91–3.
- 52 Katz J, Benoist C, Mathis D. Major histocompatibility complex class I molecules are required for the development of insulitis in non-obese diabetic mice. Eur J Immunol 1993; 23: 3358–60.
- 53 Serreze DV, Leiter EH, Christianson GJ, Greiner D, Roopenian DC. Major histocompatibility complex class I-deficient NOD-B2mnull mice are diabetes and insulitis resistant. Diabetes 1994; 43: 505–9.
- 54 Wicker LS, Leiter EH, Todd JA, Renjilian RJ, Peterson E, Fischer PA, et al. Beta 2-microglobulin-deficient NOD mice do not develop insulitis or diabetes. Diabetes 1994; 43: 500–4.
- 55 Zhang GX, Ma CG, Xiao BG, Bakhiet M, Link H, Olsson T. Depletion of CD8+ T cells suppresses the development of experimental autoimmune myasthenia gravis in Lewis rats. Eur J Immunol 1995; 25: 1191–8.
- 56 Tada Y, Ho A, Koh D, Mak TW. Collagen-induced arthritis in CD4- or CD8-deficient mice: CD8+ T cells play a role in initiation and regulate recovery phase of collagen-induced arthritis. J Immunol 1996; 156: 4520–6.
- 57 Larsson P, Goldschmidt TJ, Klareskog L, Holmdahl R. Oestrogen-mediated suppression of collagen-induced arthritis in rats: studies on the role of the thymus and peripheral CD8+ T lymphocytes. Scand J Immunol 1989; 30: 741–7.
- 58 Ehinger M, Vestberg M, Johnasson ACM, Johanesson M, Svensson A, Holmdahl R. Influence of CD4 or CD8 deficiency on collagen-induced arthritis. Immunology 2001; 103: 291–300.
- 59 Moore KJ, Wada T, Barbee SD, Kelley VR. Gene transfer of RANTES elicits autoimmune renal injury in MRL-Faslpr mice. Kidney Int 1998; 53: 1631–8.
- 60 Wada T, Furuichi K, Segawa C, Shimizu M, Sakai N, Takeda S, et al. MIP-1α and MCP-1 contribute to crescents and interstitial lesions in human crescentic glomerulonephritis. Kidney Int 1999; 56: 995–1003.
- 61 Luster AD. Chemokine-chemotactic cytokines that mediate inflammation. N Engl J Med 1998; 338: 436–45.
- 62 Matsumoto M, Sudo T, Saito T, Osada H, Tsujimoto M. Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-κB ligand (RANKL). J Biol Chem 2000; 275: 31155–61.
- 63 Matsumoto M, Sudo T, Maruyama M, Osada H, Tsujimoto M. Activation of p38 mitogen-activated protein kinase is crucial in osteoclastogenesis induced by tumor necrosis factor. FEBS Lett 2000; 486: 23–8.
- 64 Wada T, Furuichi K, Sakai N, Iwata Y, Yoshimoto K, Shimizu M, et al. A new anti-inflammatory compound, FR167653, ameliorates crescentic glomerulonephritis in Wistar-Kyoto rats. J Am Soc Nephrol 2000; 11: 1534–41.
- 65 Gardiner SM, Kemp PA, March JE, Bennett T. Influence of FR 167653, an inhibitor of TNF-alpha and IL-1, on the cardiovascular responses to chronic infusion of lipopolysaccharide in conscious rats. J Cardiovasc Pharmacol 1999; 34: 64–9.
